Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Spinnaker Trust

Spinnaker Trust cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.4% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 875 shares of the medical research company’s stock after selling 50 shares during the period. Spinnaker Trust’s holdings in Thermo Fisher Scientific were worth $464,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of the business. K.J. Harrison & Partners Inc bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $2,748,000. Herold Advisors Inc. boosted its stake in Thermo Fisher Scientific by 16.1% during the fourth quarter. Herold Advisors Inc. now owns 1,729 shares of the medical research company’s stock valued at $918,000 after buying an additional 240 shares in the last quarter. Bryn Mawr Capital Management LLC boosted its stake in Thermo Fisher Scientific by 14.0% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 10,109 shares of the medical research company’s stock valued at $5,366,000 after buying an additional 1,243 shares in the last quarter. Stevens Capital Management LP bought a new position in Thermo Fisher Scientific during the fourth quarter valued at about $503,000. Finally, Syon Capital LLC boosted its stake in Thermo Fisher Scientific by 59.0% during the fourth quarter. Syon Capital LLC now owns 3,350 shares of the medical research company’s stock valued at $1,778,000 after buying an additional 1,243 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Activity

In other news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the sale, the chief executive officer now owns 49,155 shares in the company, valued at $27,311,992.65. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,277 shares of company stock worth $28,513,384. Company insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on TMO shares. Evercore ISI raised their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Citigroup started coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target for the company. The Goldman Sachs Group increased their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Royal Bank of Canada increased their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Finally, Raymond James increased their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $606.76.

Thermo Fisher Scientific Stock Performance

TMO traded up $1.87 on Friday, hitting $573.60. The company had a trading volume of 1,438,184 shares, compared to its average volume of 1,317,052. The company’s fifty day moving average price is $573.60 and its 200 day moving average price is $529.90. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.39. The stock has a market cap of $218.95 billion, a price-to-earnings ratio of 36.79, a price-to-earnings-growth ratio of 2.41 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping the consensus estimate of $4.70 by $0.41. The company had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. Equities analysts predict that Thermo Fisher Scientific Inc. will post 21.54 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a $0.39 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.